- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01531062
Effect of Nigella Sativa on Lipid Profiles in Elderly
February 8, 2012 updated by: Jimmy Tandradynata, Indonesia University
Effect of Nigella Sativa on Lipid Profiles in Elderly: a Randomized Double-blinded Clinical Trial
The purpose of this study is to determine whether Nigella sativa seed extracts are effective in the treatment of dyslipidemia in elderly.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Cardiovascular diseases are still common health problems worldwide.
They are major causes of morbidity and mortality in many countries.
Dyslipidemia is the main risk factor of cardiovascular events.
Despite the invention of many conventional hypolipidemic drugs, the use of traditional medicine remains high, especially in elderly patients.
However, evidence of the effectiveness of many herbs or other traditional drugs is lacking.
Nigella sativa or black seeds are traditional herbs used for years in Middle East and India.
They are believed to cure many diseases, including dyslipidemia.
Therefore, a study is needed to prove their effectiveness as their use might improve our strategy to improve patients' compliance.
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jakarta, Indonesia, 10430
- Internal Medicine Department, Faculty of Medicine, University Indonesia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age of 60 years or more
- having dyslipidemia (total cholesterol >200 mg/dL or LDL >100 mg/dL or triglyceride > 150 mg/dL or HDL < 40 mg/dL (male) or HDL < 50 mg/dL (female)
Exclusion Criteria:
- ALT or AST are two times of upper normal limit
- creatinine clearance test is below 30
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
300 mg capsule bid, 56 days
|
|
EXPERIMENTAL: Nigella sativa
Nigella sativa extracts, 300 mg twice daily
|
Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Decreased level of total cholesterol, LDL, dan triglyceride, and increased level of HDL
Time Frame: 56 days
|
56 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (ACTUAL)
December 1, 2011
Study Completion (ACTUAL)
December 1, 2011
Study Registration Dates
First Submitted
February 8, 2012
First Submitted That Met QC Criteria
February 8, 2012
First Posted (ESTIMATE)
February 10, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
February 10, 2012
Last Update Submitted That Met QC Criteria
February 8, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Nigella sativa
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemia
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)Korea, Republic of
-
Kowa Research Institute, Inc.CompletedMixed Dyslipidemia | Primary DyslipidemiaUnited States
-
Fundación del Caribe para la Investigación BiomédicaNaturmegaNot yet recruitingMixed DyslipidemiaColombia
-
Addpharma Inc.Not yet recruitingMixed DyslipidemiaSouth Korea
-
Daewon Pharmaceutical Co., Ltd.Completed
-
Addpharma Inc.RecruitingMixed DyslipidemiaKorea, Republic of
-
Hanlim Pharm. Co., Ltd.RecruitingMixed DyslipidemiaKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruiting
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Canada, Hungary, New Zealand, Poland
-
Shanghai Argo Biopharmaceutical Co., Ltd.Active, not recruiting
Clinical Trials on Nigella sative
-
Cairo UniversityCompleted
-
Liaquat University of Medical & Health SciencesUniversity of Rome Tor VergataNot yet recruitingHypertension | PrehypertensionItaly
-
Universitas AirlanggaCompleted
-
Tanta UniversityNot yet recruitingCommunity Acquired Pneumonia
-
Hôpital Universitaire SahloulCompleted
-
Tanta UniversityUnknownNigella Sativa With Beta Thalassemia MajorEgypt
-
Hôpital Universitaire SahloulCompleted
-
Indonesia UniversityUnknownHypertensionIndonesia
-
Beni-Suef UniversityUniversity of Arizona; Maternity and Children Hospital, MakkahCompletedCovid19 | ImmunodeficiencySaudi Arabia